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Abstract We report findings on a child presenting with
neonatal homocystinuria, hypomethioninaemia and se-
vere neurological symptoms, including developmental
delay and seizures. Methylmalonic aciduria was not
present. The activity of methionine synthase in fibro-
blasts was severely deficient and formation of meth-
ylcobalamin from 57Co labelled cyanocobalamin was
very low. The patients cells complemented with those of
a cblE patient but not with those of two cblG patients.
No biochemical or clinical response to injections of hy-
droxycobalamin was found. Both o treatment and on
betaine and methionine supplementation the patient, at
age 8 years, has not developed megaloblastic anaemia.
In addition, the patient is homozygous for the C677T
polymorphism in the 5,10 methylenetetrahydrofolate
reductase (MTHFR) gene and the concomitant existence
of this mutation with the methionine synthase defect
may prevent folate «trapping» and thus anaemia.
Conclusion We report the lack of megaloblastic
anaemia in a patient with severe methionine synthase
deficiency who is also homozygous for C677T in
MTHFR, hypothesize that the MTHFR polymorphism
protects the patient against anaemia and speculate that
homozygosity for MTHFR C677T could cause the
dissociation between haematological and neurological
disease seen in some patients with vitamin B12
deficiency.
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Abbreviations MS methionine synthase á MeCbl
methylcobalamin á AdoCbl adenosylcobalamin á
OH-Cbl hydroxycobalamin á CN-Cbl
cyanocobalamin á PEG polyethyleneglycol á MTHFR
5,10 methylenetetrahydrofolate reductase á THF
tetrahydrofolate á MMA methylmalonic aciduria
Introduction
The remethylation of homocysteine to methionine is
catalysed by the cytoplasmic enzyme 5-methyltetrahy-
drofolate:homocysteine methyltransferase (EC 2.1.1. 13)
also called methionine synthase (MS) (Fig. 1). The en-
zyme requires methylcobalamin (MeCbl) for activity.
Another cobalamin derivative, adenosylcobalamin
(AdoCbl), is used as cofactor for the mitochondrial en-
zyme methylmalonyl-CoA mutase.
Functional MS deficiency is characterised by homo-
cystinuria and hypomethioninaemia in the absence of
methylmalonic aciduria (MMA). Patients with func-
tional MS defects are divided into two classes, cblE and
cblG, on the basis of complementation analysis [23, 24].
CblE patients have low MS activity in fibroblasts only
when reducing conditions are suboptimal, while cblG
patients show low activity under all conditions.
Among 11 reported CblE and G patients all have, at
least to some degree, responded biochemically and
clinically to therapy with hydroxycobalamin (OH-Cbl),
some also to cyanocobalamin (CN-Cbl) [24]. All the
patients have had various neurological symptoms
and megaloblastic anaemia, although one patient
presented in adulthood mainly with neurological
problems [3].
The currently more accepted hypothesis for the
occurrence of megaloblastic anaemia in patients with
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vitamin B12 deficiency and genetic MS defects is «folate
trapping» [11]. Since the reduction of 5,10-methylene-
tetrahydrofolate (5,10-methyleneTHF) to 5-methyltetra-
hydrofolate (methylTHF) by 5,10-methylenetetrahydro-
folate reductase (MTHFR) is essentially irreversible
under physiological conditions folate is «trapped» as
methylTHF. Subsequent lack of regeneration of folate
coenzymes including 5,10-methyleneTHF leads to
reduced thymidylate synthesis (Fig. 1). In patients with
vitamin B12 deficiency neurological symptoms are gen-
erally considered to be late manifestations of cobalamin
deficiency, although it is well recognised that some
patients may have a neurological disorder without
megaloblastic anaemia [15].
Recently a polymorphism in the MTHFR gene
resulting in a thermolabile enzyme was reported [8].
Individuals homozygous for this polymorphism have
slightly elevated homocysteine levels, indicating some
impairment of the enzyme in vivo. The frequency of
the homozygous state for the polymorphism was 5%
in a Dutch population [8] and 18% in a British pop-
ulation [1].
We report here on a patient with severe MS deficiency
belonging to the cblG complementation class, who is
also homozygous for the polymorphism in the MTHFR
gene. The patient diers from previously reported pa-
tients with defective MS, clinically by the lack of
megaloblastic anaemia and by the lack of a biochemical
response to cobalamin administration. The biochemical
characteristics may be explained by the severely reduced
MSmRNA found in this patient [10].
Case report
The patient is the third child of healthy, unrelated, Norwegian
parents. The pregnancy and delivery was normal and the birth
weight 3100 g. Shortly after birth the boy showed failure to thrive
and he was admitted to hospital at 6 weeks of age after two
episodes of seizures. On investigation the child was dystrophic,
severely hypotonic and showed no reaction to visual or audi-
tory stimuli. Biochemical investigations revealed homocystinuria
(66–208 lmol/mmol creatinine), homocystinaemia (31–42 lmol/l;
severe hypomethioninaemia (2–3 lmol/l; normal 14–30) and no
MMA. The initial haemoglobin value, 11.7 g/dl, and other hae-
matological parameters were close to normal for age (Table 1).
Between 8 and 14 weeks of age the patient received two blood
transfusions due to declining haemoglobin values. Also three in-
jections of 1 mg of OH-Cbl and oral folic acid (1 mg/day) was
given within a 2-week period, but with no definite clinical or bio-
chemical response. The reticulocyte count, however, which was 4%
immediately before the OH-Cbl treatment, increased to 12% 1
week after the last injection of OH-Cbl. At the age of 14 weeks the
haemoglobin value stabilised at 10 g/dl and therapy was started
with 3 ´ 0.5 g of betaine, increasing to 3 ´ 1 g/day, and folic acid,
3 ´ 5 mg/day. Plasma homocystine (free) decreased from 20 to
3 lmol/l and methionine increased from 2 to 14 lmol/l within 2
days, and he became less lethargic and fed better. He continued on
this treatment until 17 months of age when folic acid was stopped,
although betaine treatment was continued. His haematological
status did not alter after stopping folic acid. An examination of
bone marrow at the age of 22 months showed a normal erythro-
poiesis and no hypersegmentation of neutrophils or giant meta-
myelocytes. A second trial of OH-Cbl therapy, 1 mg daily for 5
weeks, was undertaken at the age of 23 months, but again with no
apparent clinical and negligible biochemical eect and it was
therefore discontinued after 5 weeks. L-Methionine supplementa-
tion (50 mg/kg/day) was started at the age of 2 years 7 months
following the finding of low levels of adenosylmethionine 124 nmol/
l (normal 131–450) and methionine 0.8 lmol/l (normal 1.1–13.5) in
CSF (analysis performed by Dr. R. Surtees, London) [20].
At the age of 3 years 4 months his gross and fine motor skills
were estimated as equivalent to a developmental stage of 10
months. His mental ability was dicult to evaluate, he could not
speak and he uttered only a few sounds. Vision and hearing had not
been investigated by function tests. He had continuous rotating eye
movements, but grasped at toys held before him and responded
towards auditory stimuli. He recognised his parents, showed dis-
crimination and had a continuous development of skills. His weight
was 12.2 kg (<10th percentile) and height 90 cm (<2.5th percen-
tile). A cerebral CT scan showed evidence of slight atrophy but this
was less marked than at the age of 8 weeks. The EEG was normal.
Essential haematological parameters are given in Table 1. Total
homocysteine in plasma was 113/lmol/l. Other parameters at the
age of 3 years 4 months were (normal values in parenthesis): leu-
cocytes 12.4 ´ 109/l (6–17.5), platelets 487 ´ 109/l (150–400), red
cell count 3.7 ´ 1012/l (3.9–5.3), reticulocytes 1.3% (<2), vitamin
B12 (total) 1001 pmol/l (100–700), serum folate >54 nmol/l (4–
20), red cell folate 1185 nmol/l (340–1150), serum iron 17 lmol/l
(8.9–21.5), serum ferritin 19 mg/l (7–140). A peripheral blood
smear showed no obvious pathological changes.
The patient was lost to follow up from the age of 4–8 years. At
the age of 8 years he was readmitted to hospital with seizures. His
Fig. 1 A simplified schematic representation of the interrelation
between vitamin B12 and folate dependent enzymes
Table 1 Haematological parameters at presentation, age 6 weeks, and at age 3 years 4 months and 8 years (treatment is with betaine
1.5 g ´ 3/day and L-methionine 50 mg/kg/day). Normal values in parenthesis
Hb g/100 ml Hct % MCV fl MCH pg MCHC g/100 ml
6 weeks 11.7 (9–14) 33 (28–42) 98 (77–115) 35 (26–34) 36 (29–37)
3 years 4 months 10.3 (11.5–13.5) 31 (34–40) 82 (75–87) 27 (24–30) 33 (31–37)
8 years 12.4 (11.5–15.5) 37 (35–45) 90 (77–95) 30 (25–33) 33 (31–37)
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plasma methionine level was undetectable and total homocysteine
in plasma was 100 lmol/l, but his haematological status was nor-
mal (Table 1). Information on compliance to treatment prior to
hospitalisation was not available. On anticonvulsive treatment he
recovered quickly. He has never developed any language, but can
walk, recognises his parents and grasps at objects held before him.
His weight is 18.4 kg (10th percentile), height 116 cm (<2.5th
percentile) and head circumference 49 cm (<2.5th percentile).
Methods
Amino acids and homocystine (free) in plasma and urine were
analysed using a Biotronik LC 5001 amino acid analyser with
ninhydrin detection. For total homocysteine in plasma the proce-
dure was as follows: 0.5 ml of plasma was mixed with 0.5 ml Li-
citrate buer, 0.2 M pH 8.2, dithiotreitol, 3 mg, was added and the
pH adjusted to 8.0–8.5 with NaCO3. After 1 h at room temperature
protein was precipitated with sulphosalicylic acid, 50 mg, the
sample was centrifuged and the supernatant injected on the Bio-
tronik amino acid analyser.
Fibroblasts were cultured in Eagle minimum essential medium
(MEM) with 10% fetal calf serum as previously reported [6]. MS
activity in fibroblasts was measured in cell extracts incubated with
14C methyltetrahydrofolate, homocysteine, S-adenosylmethionine,
b-mercaptoethanol (150 mmol/l, high reducing conditions) and
methylcobalamin, essentially as described [18]. Labelled methionine
was separated on a Dowex 1 column. Methionine and serine
formed from 14C formate in fibroblasts were measured in cells in
monolayer incubated with 14C formate and homocysteine for 16 h
as previously described [6] but using 14C formate as the labelled
compound [2]. Labelled methionine and serine were determined in
precipitated proteins after oxidation and hydrolysis by high voltage
electrophoresis [7]. Analysis of cobalamin coenzyme distribution in
plasma was performed with HPLC and a radioisotope dilution
assay as previously reported [22]. The blood sample was collected
in the dark in tubes containing EDTA. The plasma was stored at
)20°C, shielded from light. The synthesis of cobalamin coenzymes
in cultured fibroblasts was studied as reported [12]; cells were
grown for 3–5 days in MEM, then the medium was changed to
MEM containing human serum and 57Co labelled CN-Cbl and
then incubated for a further 4 days. The cells were harvested in the
dark, cobalamins extracted with ethanol (80°C), separated by
HPLC and radioactivity measured in fractions corresponding to
marker cobalamins. Complementation studies were performed in
fibroblasts fused with polyethyleneglycol (PEG) essentially as pre-
viously reported [9]; then methionine formation was measured as
described above. Radioactively labelled compounds were pur-
chased from Amersham, UK.
The activity of MTHFR in fibroblasts was determined as pre-
viously reported [17]. Analysis of the C677T mutation in the
MTHFR gene was performed as described [8].
Results
Table 2 shows MS activity (‘‘total’’ enzyme with high
reducing conditions) in fibroblasts from the patient with
dierent concentrations of MeCbl in the assay. The
patient’s cells revealed very low enzyme activity with
negligible response to high concentrations of MeCbl
regardless of whether cells were grown in medium sup-
plemented with OH-Cbl. Methionine and serine forma-
tion from labelled formate, (Table 3), is low in intact
cells from the patient and there is no increase above
expected variation of the assay following addition of
very high concentrations of OH-Cbl, MeCbl or folate to
the culture medium. The results of the complementation
study with cells from the patient and cblE and cblG
patients are shown in Fig. 2. Complementation was
obtained with cells from a cblE patient; after fusion the
formation of methionine increased approximately 15
times. No complementation was observed with cells
from two cblG patients. Fig. 3 shows the formation of
cobalamin coenzymes from 57Co labelled CN-Cbl in fi-
broblasts from the patient and also the percentage dis-
tribution of cobalamin coenzymes in the patients plasma
at the age of 1.5 years. The total cobalamin uptake in
fibroblasts from the patient was normal, 127 pg/mg
Fig. 2 Complementation studies between the cells from the patient
and cells from one cblE and two cblG patients (cblG1 and cblG2). In
experiments performed in duplicates or triplicates (Pat/CblE) the dots
represent the single values. Intact methionine biosynthesis was
measured by the incorporation of 14C formate as described in
Methods. Fusion was performed by exposing the cells to PEG. Note
that the individual cells treated with PEG may show an increased
methionine formation of 23%–89%
Fig. 3 Synthesis of cobalamin coenzymes in cultured fibroblasts from
the patient and the distribution of cobalamin coenzymes in plasma,
compared with controls (fibroblasts, n = 10, plasma n = 15). The
vertical bars (control values) represent mean  SD. Plasma was
sampled at age 1.5 years on treatment with betaine 1 g ´ 3/day. Folic
acid was stopped 3 weeks prior to the investigation. The methods are
as described in the text
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protein (controls n = 10, 113, range 40–305), but the
fraction of MeCbl in these cells was only 2.7% com-
pared to 40%–76% in controls, whereas the fraction of
AdoCbl was highly increased. Also in plasma there was
a low percentage of MeCbl and a highly increased
fraction of AdoCbl. The concentration of MeCbl in
plasma was, however, 126 pmol/l which is within the
normal range 182  50 (mean  SD). AdoCbl con-
centration in plasma was highly increased, 548 pmol/l
(normal 32  10). The recovery of cobalamin coen-
zymes extraction from plasma was 87%.
The MTHFR activity in fibroblasts from the patient
was 2.4 nmol/h per milligram protein in the absence of
added FAD (controls, n = 24, mean 6.9, range 3.0–16)
and 3.9 with added FAD (controls, n = 32, mean 8.5,
range 3.2–16). The activity of methylmalonylCoA mu-
tase was normal (results not shown).
The patient was homozygous for the C677T mutation
in the MTHFR gene (Fig. 4). Assay of MTHFR activity
in fibroblasts confirmed a thermolabile enzyme. In a
population of 423 healthy Norwegians, 18–70 years of
age, we found 8.6% to be homozygous for this mutation.
Discussion
The biochemical findings in the patient demonstrate a
functional MS deficiency in the cblG complementation
class. However, both clinically and biochemically the
patient diers from previously reported patients with
functional MS deficiency. In our patient the in vitro
deficiency of MS activity, only 1% (of mean control)
residual activity, is more severe than the 8%–18%
reported in most other cblG patients [24] and the enzyme
activity of our patient could not be stimulated by sup-
plementation of cobalamin in the medium of cultured
cells, or by addition of cofactors in the assay. In con-
trast, all but one of the seven previously reported cblG
patients have shown increased fibroblast MS activity
after supplementation of the culture medium with OH-
Cbl [23, 24]. The lack of in vitro stimulation by OH-Cbl
is in agreement with the poor biochemical response to
therapy with OH-Cbl. Also the distribution of cobal-
amin coenzymes formed from labelled CN-Cbl in fi-
broblasts of the patient was even more abnormal than in
previously reported patients [24], with very low MeCbl
formation and highly increased AdoCbl.
Table 2 MS activity in extracts
of cultured fibroblasts from the
patient grown with (+) or
without ()) OH-Cbl supple-
mentation (1 mg/l, 750 nmol/l),
and assayed with and without
addition of MeCbl (mean of
2–5 determinations). The
activities of two cblG patients
(cblG1 and cblG2) and of
controls (mean  SD and
range) are also given
MS activity
(pmol/min/mg protein)
(mean  SD; range)
Patient, )OH-Cbl, )MeCbl 1.0
+OH-Cbl, )MeCbl 1.3
)OH-Cbl, MeCbl 50 lmol/l 1.5
+OH-Cbl, MeCbl 50 lmol/l 1.6
)OH-Cbl, MeCbl 2000 lmol/l 2.0
cblG1, )OH-Cbl, MeCbl 50 lmol/l 31
cblG2, )OH-Cbl, MeCbl 50 lmol/l 19
Controls (n = 14), )OH-Cbl, MeCbl 50 lmol/l 98  21 (60–150)
Controls (n = 11), +OH-Cbl, MeCbl 50 lmol/l 320  170 (140–810)
Table 3 Methionine and serine
formed from 14C formate in fi-
broblasts from the patient with
cells grown in normal medium




(mean  SD; range)
Patient’s cells in
normal medium
0.1  0.04 (0.03–0.15) 0.35  0.32 (0.15–0.91)
OH-Cbl 1 mg/l 0.14
OH-Cbl 100 mg/l 0.08
folate 100 mg/l 0.14
MeCbl 1 mg/l 0.21
Control cells (n = 22) 3.5  1.1 (2–7) 5.2  2.1 (3–10.2)
Fig. 4 Agarose gel electrophoresis of a 198 bp, HinfI digested, PCR
product across the C677T mutation in the MTHFR gene from the
patient and controls. The C677T mutation introduces a restriction site
for HinfI and the mutated allele is digested into fragments of 175 and
23 bp, whereas alleles without the mutation remain undigested. Lane
1, control without the C677T mutation; lane 2, control heterozygous
for C677T; lane 3, control homozygous for C677T; lane 4, the patient
and; lane 5, undigested PCR product from the patient. The 23 bp
fragment is not seen
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The MS gene was recently cloned [13, 14] and the
mRNA level studied in two CblG patients, one of them
being the present patient. In contrast to the other CblG
patient studied our patient had a severe reduction of
MSmRNA. The resulting lack of MS protein may ex-
plain the severe biochemical defect together with the
lack of clinical response to OH-Cbl.
Despite severe neurological symptoms, the patient
had not developed overt megaloblastic anaemia by the
age of 8 years. The lack of megaloblastic anaemia is not
easily explained on the basis of the molecular defect of
MS. Presumably the lack of anaemia might be due to an
eect of the treatment or to other constitutional factors.
It is possible that folic acid treatment may have masked
an early development of megaloblastic anaemia but
against this is the fact that he has not developed anaemia
in the absence of folic acid for more than 6 years.
Chanarin et al. [4, 5] claim that formate resulting from
conversion of methionine to methylthioribose acts as a
supply of one carbon units for the folate cycle. According
to this hypothesis the betaine treatment and methionine
supplementation given to the patient could restore the
folate cycle and overcome the assumed deficiencies of
folate coenzymes caused by the MS defect. Also the
normal plasma concentration of MeCbl might indicate
maintenance of the folate cycle despite a lack of me-
thionine formation from homocysteine in some tissues.
A possible intriguing explanation of the lack of
anaemia in this MS deficient patient is the modulating
eect by the concomitant homozygosity for the C677T
mutation in the MTHFR gene. This mutation renders
the enzyme somewhat impaired and possibly more of the
folate derivatives remain in the reduced folate coenzyme
pool rather than being trapped by conversion to meth-
ylTHF, thus keeping the cellular level of 5,10-meth-
yleneTHF sucient for adequate thymidylate synthesis.
Furthermore, the presumed improved level of S-adeno-
sylmethionine due to the betaine treatment and me-
thionine supplementation may have added to a reduced
conversion of 5,10-methyleneTHF to methylTHF since
S-adenosylmethionine is an allosteric inhibitor of
MTHFR. If the absence of megaloblastic anaemia in
this MS deficient patient is mainly due to the concomi-
tant existence of the mutated MTHFR gene, a similar
explanation may account for the dissociation of neuro-
logical and haematological disease seen in some patients
with acquired vitamin B12 deficiency [15].
In contrast to the lack of megaloblastic anaemia the
neurological symptoms of the patient were severe from
early infancy. Initiation of betaine treatment improved
the clinical symptoms, and possibly methionine supple-
mentation may also have had a beneficial eect. This
might be explained by the presumed subsequent increase
of S-adenosylmethionine formation, shown by Surtees
et al. [21] to be deficient in CSF of patients with various
inborn errors of the methyl-transfer pathway, and to be
associated with demyelination.
Determination of the exact molecular defect of the
present and other MS deficient patients will help to
delineate the various clinical and biochemical pheno-
types of MS defect. Further investigations into the re-
lationship between genetic or acquired MS defects and
the polymorphism in the MTHFR gene may also give
new insight into the complex interaction of folate and
vitamin B12 metabolism. Finally the unusual features of
this patient emphasise the need to screen patients with
neurological disorders, but without megaloblastic
anaemia, for homocystinuria due to MS deficiency.
References
1. Bonham JR, Moat SJ, Guthrie PAI, Olpin SE, Tanner MS,
Makis M (1996) The thermolabile methylenetetrahydrofolate
reductase (MTHFR) mutation - a common finding in the UK
population. J Inherit Metab Dis 19 [Suppl]:23 (P46)
2. Boss GR (1985) Cobalamin inactivation decreases purine and
methionine synthesis in cultured lymphocytes. J Clin Invest
76:213–218
3. Carmel R, Watkjins D, Goodman SI, Rosenblatt DS (1988)
Hereditary defect of cobalamin metabolism (cblG mutation)
presenting as a neurological disorder in adulthood. N Engl J
Med 318:1738–1741
4. Chanarin I, Deacon R, Lumb M, Perry J (1980) Vitamin B12
regulates folate metabolism by the supply of formate. Lancet
6:505–507
5. Chanarin I, Deacon R, Lumb M, Perry J (1989) Cobalamin-
folate interrelations. Blood 3:211–215
6. Fowler B (1982) Transsulfuration and methylation of homo-
cysteine in control and mutant human fibroblasts. Biochem
Biophys Acta 721:201–207
7. Fowler B, Whithouse C, Wenzel F, Wraith JEW (1997) Me-
thionine and serine formation in control and mutant human
cultured fibroblasts: evidence for methyl trapping and charac-
terization of remethylation defects. Pediatr Res 41:145–151
8. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mat-
thews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den
Heuvel LP, Rozen R (1995) A candidate genetic risk factor for
vascular disease: a common mutation in methylenetetra-
hydrofolate reductase. Nat Genet 10:111–113
9. Gravel R, Lewry A, Saunders M, Ho¨sli P (1979) Analysis of
genetic complementation by wholecell microtechniques in fi-
broblast heterokaryons. Proc Natl Acad Sci 76:6520–6524
10. Gulati S, Baker P, Li YN, Fowler B, Kruger W, Brody LC,
Banjeree R (1996) Defects in human methionine synthase in
CblG patients. Hum Mol Gene 12:1859–1856
11. Hobrand AV, Jackson BF (1993) Correction of the DNA
synthesis defect in vitamin B12 deficiency by tetrahydrofolate:
evidence in favour of the methyl-folate trap hypothesis as the
cause of megaloblastic anaemia in vitamin B12 deficiency. Br J
Haematol 83:643–647
12. Jacobsen DW, Green R, Quadros EV, Montejado YD (1982)
Rapid analysis of cobalamin coenzymes and related corrinoid
analogs by high-performance liquid chromotography. Analyt
Biochem 120:394–403
13. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B,
Ross M, Eydoux P, Rosenblatt DS, Rozen R, Grvel RA (1996)
Human methionine synthase: cDNA cloning and identification
of mutations in patients of the cblG complementation group of
folate/cobalamin disorders. Hum Mol Gene 12:1867–1874
14. Li YN, Gulati S, Baker PJ, Brody LC, Banjeree R, Kruger WD
(1996) Cloning, mapping and RNA analysis of the human
methionine synthase gene. Hum Mol Gene 12:1851–1856
15. Lindenbaum J, Healton EB, Savage DG, Brust JCM, Garrett
TJ, Podell ER, Marcell PD, Stabler SP, Allen RH (1988)
Neuropsychiatric disorders caused by cobalamin deficiency in
the absence of anemia or macrocytosis. N Engl J Med
318:1720–1728
929
16. Mellman I, Willard HF, Youngdahl-Turner P, Rosenberg LE
(1979) Cobalamin coenzyme synthesis in normal and mutant
fibroblasts:evidence for a processing enzyme activity deficient in
cblC cells. J Biol Chem 254:11847–11853
17. Rosenblatt DS, Erbe RW (1977) Methylenetetrahydrofolate
reductase in cultured human cells. I. Growth and metabolic
studies. Pediatr Res 11:1137–1141
18. Rosenblatt DS, Cooper BA, Pottier A, Lue-Shing H, Matiaszuk
N, Grauer Kity (1984) Altered vitamin B12 metabolism in fi-
broblasts from a patient with megaloblastic anemia and homo-
cystinuria due to a new defect in methionine biosynthesis. J Clin
Invest 74:2149–2156
19. Sillaots SL, Hall CA, Hurteloup V, Rosenblatt DS (1992)
Heterogeneity in cblG. Dierential retention of cobalamin on
methionine synthase. Biochem Med Metab Biol 47:242–249
20. Surtees R, Hyland K (1990) Cerebrospinal fluid concentrations
of S-adenosylmethionine, methionine, and 5-methyltetra-
hydrofolate in a reference population:cerebrospinal fluid
S-adenosylmethionine declines with age in humans. Biochem
Med Metab Biol 44:192–199
21. Surtees R, Leonard J, Austin S (1991) Association of demye-
lination with deficiency of cerebrospinal-fluid S-adenosyl-
methionine in inborn errors of methyl-transfer pathway. Lancet
338:1550–1554
22. Van Kapel J, Spijkers LJM, Lindemans J, Abels J (1983) Im-
proved distribution analysis of cobalamins and cobalamin an-
alogues in human plasma in which the use of thiol-blocking
agents is a prerequisite. Clin Chim Acta 131:211–214
23. Watkins D, Rosenblatt DS (1988) Genetic heterogeneity among
patients with methylcobalamin deficiency. Definition of
two complementation groups, cblE and cblG. J Clin Invest
81:1690–1694
24. Watkins D, Rosenblatt DS (1989) Functional methionine syn-
thase deficiency (cblE and cblG): clinical and biochemical het-
erogeneity. Am J Med Genet 34:427–434
930
